day0

Revive has the potential to surpass $3 to $13 within 4 years.

Long
OTC:RVVTF   Revive Therapeutics Ltd
This forecast is not financial advice. Please be responsible and speak with professional financial advisors. Please do your own research and create your own opinions. All comments below are also not financial advice. Markets can shift both up and down and down and up, so please be very careful.
Comment: 2021-05-17 (May 17th): “Revive positioned itself as an innovator of novel uses and delivery forms of psilocybin, as a potential treatment for unmet medical needs. Revive, with our relationship with LTS, will be able to expedite its clinical and commercial ambitions with psilocybin as a pharmaceutical, globally.”

2021-05-03 (May 3rd): "Dr. Fahy is the senior author of a recent study, titled “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry” showing that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. These findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provide rationale to test thiol-based drugs such as Bucillamine as novel treatments for COVID-19".

2021-04-27 (April 27th): "Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury" and "In preclinical studies conducted at the National Health Research Institutes"... "It was found that psilocybin, given after injury, improved cognitive function in TBI mice. Also, there were no adverse effects observed with psilocybin".

Press Release Source: https://revivethera.com/news/
Comment: Perhaps, $0.93 by 2022-03-31 if the current monthly trend continues (bottom green line displayed on the forecast above).
Comment: Deflation slowing purchases (NOV 8th (weekly data) ); leading to a decline in prices. This chart compares Deflation to BTC.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.